Pharmacotherapy of arterial hypertension in patients with psoriasis
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111531" target="_blank" >RIV/00843989:_____/25:E0111531 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/61988987:17110/25:A2603DG4
Výsledek na webu
<a href="https://journals.lww.com/jhypertension/fulltext/2025/04000/pharmacotherapy_of_arterial_hypertension_in.2.aspx" target="_blank" >https://journals.lww.com/jhypertension/fulltext/2025/04000/pharmacotherapy_of_arterial_hypertension_in.2.aspx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/HJH.0000000000003982" target="_blank" >10.1097/HJH.0000000000003982</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Pharmacotherapy of arterial hypertension in patients with psoriasis
Popis výsledku v původním jazyce
Psoriasis is a chronic systemic autoimmune disease associated with an elevated risk of developing cardiovascular disease. In patients with psoriasis, arterial hypertension treatment requires careful selection of antihypertensive drugs, as some drugs may worsen the skin manifestations of psoriasis. In this review, we summarize the available evidence regarding the risks and benefits of each group of antihypertensive drugs. We also suggest a scheme for optimizing antihypertensive treatment in patients with psoriasis, with emphasis on achieving effective control of blood pressure and cardiovascular disease, while minimizing the worsening of cutaneous manifestations. Angiotensin receptor blockers appear to be the most appropriate treatment for hypertensive patients with psoriasis, with the potential addition of calcium channel blockers if blood pressure is not adequately controlled. Alternatives are angiotensin-converting enzyme inhibitors and/or mineralocorticoid receptor antagonists. Diuretics and beta blockers are associated with greater risk of worsening of psoriatic lesions.
Název v anglickém jazyce
Pharmacotherapy of arterial hypertension in patients with psoriasis
Popis výsledku anglicky
Psoriasis is a chronic systemic autoimmune disease associated with an elevated risk of developing cardiovascular disease. In patients with psoriasis, arterial hypertension treatment requires careful selection of antihypertensive drugs, as some drugs may worsen the skin manifestations of psoriasis. In this review, we summarize the available evidence regarding the risks and benefits of each group of antihypertensive drugs. We also suggest a scheme for optimizing antihypertensive treatment in patients with psoriasis, with emphasis on achieving effective control of blood pressure and cardiovascular disease, while minimizing the worsening of cutaneous manifestations. Angiotensin receptor blockers appear to be the most appropriate treatment for hypertensive patients with psoriasis, with the potential addition of calcium channel blockers if blood pressure is not adequately controlled. Alternatives are angiotensin-converting enzyme inhibitors and/or mineralocorticoid receptor antagonists. Diuretics and beta blockers are associated with greater risk of worsening of psoriatic lesions.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30201 - Cardiac and Cardiovascular systems
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of hypertension
ISSN
0263-6352
e-ISSN
1473-5598
Svazek periodika
43
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
9
Strana od-do
568-576
Kód UT WoS článku
001429352400023
EID výsledku v databázi Scopus
2-s2.0-85218827110